Literature DB >> 437836

Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC).

N Sato, Y Yabuki, K Toh, Y Ishii, K Kikuchi.   

Abstract

The nature of cell-dependent antibody (CDA) and the mechanism of inhibition of antibody-dependent cellular cytotoxicity (ADCC) were studied in the ADCC assay system in which culture cells of methylcholanthrene-induced rat fibrosarcoma (KMT-50) were used as target cells, xenogeneic antiserum (rabbit anti-KMT-50) as the CDA, and human peripheral blood leucocytes (PBL) as effector cells, respectively. By using protein-A Sepharose CL-4B affinity column chromatography of rabbit anti-KMT-50 serum, CDA was shown to bind protein A. Complement dependent-cytotoxicity (CDC), however, was demonstrated in both the adsorbed fraction (eluate) and the non-adsorbed fraction (effluent) to protein A from the same affinity column chromatography. These data confirmed that CDA was IgG with an intact Fc portion. Inhibition of ADCC occurred by pretreatment of effector cells with rabbit anti-effector (human PBL) serum even with extremely small amounts of antiserum. Such inhibition was demonstrated with the eluate but not with the effluent from protein-A Sepharose CL-4B affinity column chromatography of rabbit anti-effector serum. F(ab')2 fragments of the same eluate (IgG) did not inhibit the ADCC activity. These data showed that the inhibition of ADCC was induced by the blocking of Fc receptors of effector cells with the Fc portions of IgG in anti-effector serum. The data obtained indicate the usefulness of protein A in separation and analysis of CDA and in investigation of the inhibitory mechanisms of ADCC.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 437836      PMCID: PMC1457564     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds.

Authors:  A NISONOFF; F C WISSLER; L N LIPMAN; D L WOERNLEY
Journal:  Arch Biochem Biophys       Date:  1960-08       Impact factor: 4.013

2.  Mediation of macrophage cytolytic and phagocytic activities by antibodies of different classes and class-specific Fc-receptors.

Authors:  W S Walker
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

3.  ADCC effector cells in a murine adenocarcinoma. I. Evidence for blood-borne bone-marrow-derived monocytes.

Authors:  J S Haskill
Journal:  Int J Cancer       Date:  1977-09-15       Impact factor: 7.396

4.  Binding site of human IgG subclasses and their domains for Fc receptors of activated murine T cells.

Authors:  M Klein; C Neauport-Sautes; J R Ellerson; W H Fridman
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

5.  "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin.

Authors:  A Forsgren; J Sjöquist
Journal:  J Immunol       Date:  1966-12       Impact factor: 5.422

6.  Characterization of human B lymphocyte specific antigens.

Authors:  Y Ishii; H Koshiba; H Ueno; I Maeyama; T Takami
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

Review 7.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

8.  Immunologic responses to a murine mammary adenocarcinoma. II. Monocyte effector activation by humoral factors.

Authors:  Y Yamamura
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

9.  Temporal analysis of cellular cytotoxicity and humoral factors during progession and regression of Rous sarcomas in Japanese quails.

Authors:  M Hayami; M Ito; Y Yoshikawa; K Yamanouchi
Journal:  Jpn J Med Sci Biol       Date:  1976-02

10.  Studies of the human lymphocyte receptor for heat-aggregated or antigen-complexed immunoglobulin.

Authors:  H B Dickler
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.